Inclusion Criteria:  Participants must be able to provide an archived tumor sample Histologically or cytologically confirmed solid tumors with KRAS G12C mutation Must have received at least 1 prior standard therapy Must have at least 1 measurable lesion per RECIST v1.1 Must have adequate organ function Must be able to swallow and retain orally administered medication  Exclusion Criteria:  Has brain or spinal metastases, except if treated and no evidence of radiographic progression or hemorrhage for at least 28 days Active infection requiring systemic treatment within 7 days Active HBV or HCV Any severe and/or uncontrolled medical conditions LVEF ≤50% assessed by ECHO or QTcF QT interval >470 msec Experiencing unresolved CTCAE 5.0 Grade >1 toxicities